Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793644 · ClinicalTrials.gov registry record
Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients
A clinical trial of Trauma Injury and Fractures, Bone, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT06793644: Recruiting study of Trauma Injury and Fractures, Bone, sponsored by Dartmouth-Hitchcock Medical Center.
NCT06793644 is a study of Trauma Injury and Fractures, Bone that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 10 participants, below the 500-participant average among 15 other Trauma Injury trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06793644, a study of Trauma Injury and Fractures, Bone, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether an indocyanine green (ICG) fluorescence imaging system (cBPI) can be used to provide surgeons with information about bone health or bone blood flow. This will help surgeons better understand the healing potential of bone and relative risk of complication. This is important to help surgeons select the most appropriate treatment for severe traumatic injuries and infections.
Primary Outcome
All unplanned reoperations will be documented using a specific case report form
Conditions Studied
Interventions
- DRUG Immunofluorescence Imaging
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2027-10 |
What NCT06793644 shows while recruiting
NCT06793644 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 500-participant average among 15 other Trauma Injury trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Trauma Injury appearing as the primary indexed condition, and to 1 intervention - of which Immunofluorescence Imaging is the first listed.
NCT06793644 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06793644 about?
NCT06793644 is a clinical study titled "Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients". The purpose of this study is to determine whether an indocyanine green (ICG) fluorescence imaging system (cBPI) can be used to provide surgeons with information about bone health or bone blood flow. This will help surgeons better understand the healing potential of bone and relative risk of complica...
What is the current status of trial NCT06793644?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2025-06-10. Estimated completion is 2027-10.
What conditions does trial NCT06793644 study?
This clinical trial studies the following conditions: Trauma Injury, Fractures, Bone.
What interventions are being tested in trial NCT06793644?
The interventions under investigation include: Immunofluorescence Imaging (DRUG).
Who is sponsoring clinical trial NCT06793644?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06793644 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06793644's enrollment target sits among peer trials
10 16th of 15 the lowest of 15 other Trauma Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trauma Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pathological Myeloid Activation After Sepsis and Trauma
RECRUITING
-
Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries
RECRUITING · NA
-
Antibiotic Use in Facial Fracture Post Injury
RECRUITING
-
Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury
RECRUITING · NA
-
The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma
RECRUITING
-
Bioimpedance for Ortho Trauma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI